ES2865504T3 - Procedimientos y composiciones para la mejora de la función cognitiva - Google Patents

Procedimientos y composiciones para la mejora de la función cognitiva Download PDF

Info

Publication number
ES2865504T3
ES2865504T3 ES17167125T ES17167125T ES2865504T3 ES 2865504 T3 ES2865504 T3 ES 2865504T3 ES 17167125 T ES17167125 T ES 17167125T ES 17167125 T ES17167125 T ES 17167125T ES 2865504 T3 ES2865504 T3 ES 2865504T3
Authority
ES
Spain
Prior art keywords
oxo
methyl
hydrogen
alkyl
butanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17167125T
Other languages
English (en)
Spanish (es)
Inventor
Michela Gallagher
Rebecca Haberman
Ming Teng Koh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of ES2865504T3 publication Critical patent/ES2865504T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES17167125T 2008-10-16 2009-10-16 Procedimientos y composiciones para la mejora de la función cognitiva Active ES2865504T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10584708P 2008-10-16 2008-10-16
US15263109P 2009-02-13 2009-02-13
US17553609P 2009-05-05 2009-05-05

Publications (1)

Publication Number Publication Date
ES2865504T3 true ES2865504T3 (es) 2021-10-15

Family

ID=41403972

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17167125T Active ES2865504T3 (es) 2008-10-16 2009-10-16 Procedimientos y composiciones para la mejora de la función cognitiva
ES09748527.0T Active ES2637497T3 (es) 2008-10-16 2009-10-16 Procedimientos y composiciones para la mejora de la función cognitiva

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09748527.0T Active ES2637497T3 (es) 2008-10-16 2009-10-16 Procedimientos y composiciones para la mejora de la función cognitiva

Country Status (11)

Country Link
US (5) US20100099735A1 (https=)
EP (2) EP3260118B1 (https=)
JP (3) JP5917148B2 (https=)
CN (2) CN107243007A (https=)
AU (1) AU2009303834B2 (https=)
CA (1) CA2740610C (https=)
DK (2) DK3260118T3 (https=)
EA (1) EA033130B1 (https=)
ES (2) ES2865504T3 (https=)
HK (1) HK1245099A1 (https=)
WO (1) WO2010044878A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3260118T3 (da) 2008-10-16 2021-04-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
BR112013020283A2 (pt) * 2011-02-09 2016-07-19 Univ Johns Hopkins "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
US20160030391A1 (en) * 2013-03-15 2016-02-04 The Johns Hopkins University Methods and compositions for improving cognitive function
EP3297611B1 (en) * 2015-05-22 2019-07-03 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
MA43532A (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals Inc Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
US20200121644A1 (en) * 2016-05-20 2020-04-23 Institut Pasteur Methods of treating sepsis with synaptic vesicle 2a and/or 2b binding chemical entities
US10370561B2 (en) 2016-06-28 2019-08-06 Prc-Desoto International, Inc. Urethane/urea-containing bis(alkenyl) ethers, prepolymers prepared using urethane/urea-containing bis(alkenyl) ethers, and uses thereof
US11098222B2 (en) 2018-07-03 2021-08-24 Prc-Desoto International, Inc. Sprayable polythioether coatings and sealants
CN109892247B (zh) * 2019-04-19 2023-08-18 桂林医学院 一种猫参与的检测大鼠认知功能的实验装置
US20220354807A1 (en) * 2019-09-30 2022-11-10 Xiamen University Use of valeric acid derivative in treatment of down's syndrome
CA3189302A1 (en) * 2020-07-10 2022-01-13 Agenebio, Inc. Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
BR112023017222A2 (pt) * 2021-02-26 2023-11-21 Syndesi Therapeutics Sa Composto que é um triazol de 2-oxo-1-pirrolidinila substituído de fórmula (i), e, composição farmacêutica compreendendo um composto que é um triazol de 2-oxo-1-pirrolidinila substituído de fórmula (i)
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
IT1045043B (it) * 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
IT1075280B (it) * 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
ATE27T1 (de) * 1978-05-08 1981-04-15 Ucb Sa Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4372960A (en) * 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
FR2515179A1 (fr) * 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
IL67623A (en) 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
JPS6222785A (ja) * 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3709230A1 (de) * 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
JPS6422883A (en) * 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
ES2026198T3 (es) 1987-07-22 1992-04-16 Farvalsa Ag Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion.
IL93051A0 (en) 1989-01-17 1990-11-05 Hoffmann La Roche ((5-oxo-2-pyrrolidinyl)methyl)cyclohexaneacetamides,their preparation and pharmaceutical compositions containing them
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
CA2067614C (en) * 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
US5439930A (en) * 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
US5440023A (en) 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5516759A (en) 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
IT1285801B1 (it) 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
US6131106A (en) 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
CA2475026A1 (en) 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
KR100823668B1 (ko) * 2000-12-28 2008-04-21 해밀턴 파마슈티컬스 인코포레이티드 신경성 통증 치료 및 예방약
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
CA2457982C (en) * 2001-08-22 2009-11-03 Daiichi Pharmaceutical Co., Ltd. Use of nefiracetam for treating neurodegeneration
CN1604776A (zh) 2001-10-16 2005-04-06 记忆药物公司 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
JP2006516390A (ja) * 2002-12-03 2006-07-06 ユ セ ベ ソシエテ アノニム 発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
ITMI20030573A1 (it) * 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
EA010031B1 (ru) * 2003-12-02 2008-06-30 Юсб, С.А. Производные имидазола, способы их получения и применения
WO2005108358A2 (en) 2004-04-22 2005-11-17 Eli Lilly And Company Pyrrolidine derivatives useful as bace inhibitors
WO2005121082A1 (en) 2004-06-11 2005-12-22 Ucb, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
EA014249B1 (ru) * 2005-01-27 2010-10-29 Алембик Лимитед Формуляция леветирацетама длительного высвобождения
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
JP2008534522A (ja) * 2005-03-30 2008-08-28 ジェンファーム インク 医薬組成物のための複合ステップ製造方法
EP2308870A3 (en) 2005-06-01 2011-10-19 UCB Pharma S.A. 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
EP1963325A2 (en) 2005-12-07 2008-09-03 UCB Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
WO2008095221A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
WO2008132142A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
KR20090031333A (ko) 2007-09-21 2009-03-25 주식회사 엘지생명과학 신규한 베타-세크리타제 저해용 화합물
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
MX2010009222A (es) * 2008-03-03 2010-09-28 Ucb Pharma Sa Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
DK3260118T3 (da) 2008-10-16 2021-04-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
US9125898B2 (en) * 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
AU2009317280B2 (en) 2008-11-18 2014-03-06 Ucb Pharma, S.A. Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
CN104906085A (zh) 2009-01-29 2015-09-16 Ucb医药有限公司 含有2-氧代-1-吡咯烷衍生物的药物组合物
EP2393483B1 (en) 2009-02-09 2017-06-28 UCB Biopharma SPRL Pharmaceutical compositions comprising brivaracetam
WO2011015349A2 (en) 2009-08-07 2011-02-10 Ucb Pharma, S.A. Methods for enhancing the cognitive function
CA2986598C (en) * 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Also Published As

Publication number Publication date
WO2010044878A1 (en) 2010-04-22
EP3260118B1 (en) 2021-03-24
CA2740610C (en) 2020-01-07
CN107243007A (zh) 2017-10-13
JP2012505883A (ja) 2012-03-08
DK2346500T3 (en) 2017-07-17
BRPI0920342A2 (pt) 2020-06-23
EP2346500B1 (en) 2017-05-17
US20120046336A1 (en) 2012-02-23
US20150094352A1 (en) 2015-04-02
DK3260118T3 (da) 2021-04-19
CA2740610A1 (en) 2010-04-22
JP2016147915A (ja) 2016-08-18
ES2637497T3 (es) 2017-10-13
HK1245099A1 (zh) 2018-08-24
EA033130B1 (ru) 2019-08-30
US20220218665A1 (en) 2022-07-14
US20240293363A1 (en) 2024-09-05
EA201170571A1 (ru) 2011-12-30
CN102227217A (zh) 2011-10-26
JP5917148B2 (ja) 2016-05-11
EP2346500A1 (en) 2011-07-27
JP6271641B2 (ja) 2018-01-31
JP2014169339A (ja) 2014-09-18
HK1248543A1 (en) 2018-10-19
US20100099735A1 (en) 2010-04-22
AU2009303834B2 (en) 2016-08-11
AU2009303834A1 (en) 2010-04-22
EP3260118A1 (en) 2017-12-27
US8604075B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
ES2865504T3 (es) Procedimientos y composiciones para la mejora de la función cognitiva
US20230277501A1 (en) Methods and compositions for improving cognitive function
US20230033195A1 (en) Methods and compositions for improving cognitive function
WO2014144546A1 (en) Methods and compositons for improving cognitive function
HK1248543B (en) Methods and compositions for improving cognitive function
BRPI0920342B1 (pt) Uso de levetiracetam e de brivracetam, bem como de seus derivados ou análogos ou sais farmaceuticamente aceitáveis dos mesmos
HK1160007A (en) Methods and compositions for improving cognitive function
HK1160007B (en) Methods and compositions for improving cognitive function
HK1261244A1 (en) Levetiracetam for improving cognitive function
EA044839B1 (ru) Способы и композиции для улучшения когнитивной функции
HK1160005A (en) Methods and compositions for improving cognitive function